Omnicell (OMCL) 10-Q 12 May 14 2014 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information Document and Entity Information	3 Months Ended
	Mar. 31, 2014	2-May-14
Entity Information [Line Items]	'	'
Entity Registrant Name	'OMNICELL, Inc	'
Entity Central Index Key	'0000926326	'
Document Type	'10-Q	'
Document Period End Date	31-Mar-14	'
Amendment Flag	'false	'
Current Fiscal Year End Date	'--12-31	'
Entity Well-known Seasoned Issuer	'No	'
Entity Voluntary Filers	'No	'
Entity Current Reporting Status	'Yes	'
Entity Filer Category	'Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	36,605,717
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q1	'

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$107,558	$104,531
Accounts receivable, net of allowances of $710 and $490, respectively	75,496	58,597
Inventories	30,975	31,457
Prepaid expenses	16,378	18,883
Deferred tax assets	12,636	12,635
Other current assets	7,799	7,675
Total current assets	250,842	233,778
Property and equipment, net	35,178	35,254
Non-current net investment in sales-type leases	11,644	11,485
Goodwill	111,343	111,343
Intangible assets, net	80,573	81,602
Non-current deferred tax assets	1,164	1,102
Other assets	19,661	17,937
Total assets	510,405	492,501
Current liabilities:	'	'
Accounts payable	20,154	16,471
Accrued compensation	12,018	19,604
Accrued liabilities	13,494	13,746
Deferred service revenue	21,328	22,626
Deferred gross profit	25,106	19,957
Total current liabilities	92,100	92,404
Non-current deferred service revenue	19,773	17,763
Non-current deferred tax liabilities	27,926	28,162
Other long-term liabilities	5,430	5,175
Total liabilities	145,229	143,504
Stockholders' equity:	'	'
Total stockholders' equity	365,176	348,997
Total liabilities and stockholders' equity	$510,405	$492,501

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEETS (PARENTHETICAL) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Accounts receivable, allowances	$710	$490

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Revenues:	'	'
Product revenues	$82,580	$69,236
Services and other revenues	19,184	17,874
Total revenues	101,764	87,110
Cost of revenues:	'	'
Cost of product revenues	38,900	33,547
Cost of services and other revenues	8,369	8,196
Total cost of revenues	47,269	41,743
Gross profit	54,495	45,367
Operating expenses:	'	'
Research and development	6,121	7,954
Selling, general and administrative	38,420	33,244
Total operating expenses	44,541	41,198
Income from operations	9,954	4,169
Interest and other income (expense), net	-256	-223
Income before provision for income taxes	9,698	3,946
Provision for income taxes	3,504	561
Net income	$6,194	$3,385
Net income per share:	'	'
Net income per share-basic	$0.18	$0.10
Net income per share - diluted	$0.17	$0.10
Weighted average shares outstanding:	'	'
Basic (in shares)	35,225	33,900
Diluted (in shares)	36,305	34,820

CONDENSED_CONSOLIDATED_STATEME1

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Net income	$6,194	$3,385
Other comprehensive income:	'	'
Changes in fair value of foreign currency forward hedges	0	-65
Foreign currency translation adjustment	33	-203
Other comprehensive income (loss)	33	-268
Comprehensive income	$6,227	$3,117

CONDENSED_CONSOLIDATED_STATEME2

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Cash flows from operating activities:	'	'
Net income	$6,194	$3,385
Adjustments to reconcile net income to net cash provided by operating activities:	'	'
Depreciation and amortization	4,612	4,472
Loss on disposal of fixed assets	191	41
Impairment of software development costs	0	1,759
Provision for receivable allowance	217	129
Share-based compensation expense	2,729	2,926
Income tax benefits from employee stock plans	2,017	342
Excess tax benefits from employee stock plans	-2,287	-555
Provision for excess and obsolete inventories	32	451
Deferred income taxes	-299	-1,076
Changes in operating assets and liabilities:	'	'
Accounts receivable, net	-17,114	-10,706
Inventories	450	327
Prepaid expenses	2,505	-657
Other current assets	-27	1,061
Non-current net investment in sales-type leases	-239	443
Other assets	176	-463
Accounts payable	3,683	124
Accrued compensation	-7,586	-4,665
Accrued liabilities	-252	537
Deferred service revenue	712	-42
Deferred gross profit	5,149	6,166
Other long-term liabilities	254	133
Net cash provided by operating activities	1,117	4,132
Cash flows from investing activities:	'	'
Acquisition of intangible assets and intellectual property	-139	-48
Software development for external use	-2,902	-1,899
Purchases of property and equipment	-2,551	-3,300
Net cash used in investing activities	-5,592	-5,247
Cash flows from financing activities:	'	'
Proceeds from issuance of common stock under employee stock purchase and stock option plans	9,624	8,315
Employees' taxes paid related to restricted stock units	-349	-211
Common stock repurchases	-4,069	0
Excess tax benefits from employee stock plans	2,287	555
Net cash provided from financing activities	7,493	8,659
Effect of exchange rate changes on cash and cash equivalents	9	-40
Net increase in cash and cash equivalents	3,027	7,504
Cash and cash equivalents at beginning of period	104,531	62,313
Cash and cash equivalents at end of period	$107,558	$69,817

Organization_and_Summary_of_Si

Organization and Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Organization and Summary of Significant Accounting Policies	'
	Organization and Summary of Significant Accounting Policies
	Description of the Company. Omnicell, Inc. ("Omnicell," "our," "us," "we," or the "Company") was incorporated in California in 1992 under the name Omnicell Technologies, Inc. and reincorporated in Delaware in 2001 as Omnicell, Inc. Our major products are automated medication supply control systems and medical adherence solutions which are sold in our principal market, which is the healthcare industry. Our market is primarily located in the United States and Canada.
	Basis of presentation. These interim condensed consolidated financial statements are unaudited but reflect, in the opinion of management, all adjustments, consisting of normal recurring adjustments and accruals, necessary to present fairly the financial position of Omnicell and its subsidiaries as of March 31, 2014, the results of their operations, comprehensive income and cash flows for the three months ended March 31, 2014 and 2013. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (“GAAP”), have been condensed or omitted in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”). These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and accompanying notes included in our Annual Report on Form 10-K for the year ended December 31, 2013.
	Our results of operations, comprehensive income and cash flows for the three months ended March 31, 2014 are not necessarily indicative of results that may be expected for the year ending December 31, 2014, or for any future period.
	Use of estimates. GAAP requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and various other assumptions believed to be reasonable. Although these estimates are based on management's best knowledge of current events and actions that may impact the company in the future, actual results may be different from the estimates. Our critical accounting policies are those that affect our financial statements materially and involve difficult, subjective or complex judgments by management. Those policies are revenue recognition, share-based compensation, inventory valuation, valuation of goodwill and purchased intangibles, valuation of long-lived assets and accounting for income taxes.
	Principles of consolidation. The condensed consolidated financial statements include the accounts of our wholly-owned subsidiaries. All significant inter-company accounts and transactions have been eliminated in consolidation.
	Concentration of credit risk. Financial instruments that may potentially subject us to concentrations of credit risk consist principally of cash equivalents and accounts receivable. Cash equivalents are maintained with several financial institutions and may exceed the amount of insurance provided on such balances. The majority of our accounts receivable are derived from sales to customers for commercial applications. We perform ongoing credit evaluations of our customers’ financial condition and limit the amount of credit extended when deemed necessary but generally require no collateral. We maintain reserves for potential credit losses. Our products are broadly distributed and there was no single customer accounting for 10% or more of revenues in the three months ended March 31, 2014. Additionally, there was no single customer accounting for 10% or more of accounts receivable at March 31, 2014 or December 31, 2013. We believe that we have no significant concentrations of credit risk at March 31, 2014.
	Dependence on suppliers. We have a supply agreement with one primary supplier for construction and supply of several sub-assemblies and inventory management of sub-assemblies used in our hardware products. There are no minimum purchase requirements. The contract may be terminated by either the supplier or by us without cause and at any time upon delivery of two months’ notice. Purchases from this supplier for the three months ended March 31, 2014 and 2013 totaled approximately $8.9 million and $7.2 million, respectively.
	There have been no material changes in our significant accounting policies as of and for the three months ended March 31, 2014, compared to the significant accounting policies described in our Annual Report on Form 10-K for the year ended December 31, 2013.
	Recently Adopted Accounting Standards
	In July 2013, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2013-11, Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists. ASU 2013-11 requires an entity to present an unrecognized tax benefit, or a portion of an unrecognized tax benefit, as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward, except as follows: to the extent a net operating loss carryforward, a similar tax loss, or a tax credit carryforward is not available at the reporting date under the tax law of the applicable jurisdiction to settle any additional income taxes that would result from the disallowance of a tax position or the tax law of the applicable jurisdiction does not require the entity to use, and the entity does not intend to use, the deferred tax asset for such purpose, the unrecognized tax benefit should be presented in the financial statements as a liability and should not be combined with deferred tax assets. We adopted the amendments in ASU 2013-11 in the first quarter of 2014. This update did not have a significant impact on our financial position, operating results or cash flows.

Net_Income_Per_Share

Net Income Per Share	3 Months Ended
	Mar. 31, 2014
Earnings Per Share [Abstract]	'
Net Income Per Share	'
		Net Income Per Share
	Basic net income per share is computed by dividing net income for the period by the weighted average number of shares outstanding during the period, less shares subject to repurchase. Diluted net income per share is computed by dividing net income for the period by the weighted average number of shares, less shares subject to repurchase, plus, if dilutive, potential common stock outstanding during the period. Potential common stock includes the effect of outstanding dilutive stock options, restricted stock awards and restricted stock units computed using the treasury stock method. Since their impact is anti-dilutive, we excluded 347,265 and 1,865,589 shares from the calculations of diluted net income per share for the three months ended March 31, 2014 and 2013, respectively.
	The calculation of basic and diluted net income per share is as follows (in thousands, except per share amounts):
		Three Months Ended March 31,
		2014		2013
	Basic:
	Net income	$	6,194	$	3,385
	Weighted average shares outstanding — basic	35,225		33,900
	Net income per share — basic	$	0.18	$	0.1
	Diluted:
	Net income	$	6,194	$	3,385
	Weighted average shares outstanding — basic	35,225		33,900
	Add: Dilutive effect of employee stock plans	1,080		920
	Weighted average shares outstanding — diluted	36,305		34,820
	Net income per share — diluted	$	0.17	$	0.1

Cash_and_Cash_Equivalents_Shor

Cash and Cash Equivalents, Short-term Investments and Fair Value of Financial Instruments	3 Months Ended
	Mar. 31, 2014
Cash and Cash Equivalents [Abstract]	'
Cash and Cash Equivalents, Short-term Investments and Fair Value of Financial Instruments	'
	Cash and Cash Equivalents and Fair Value of Financial Instruments
	Cash and cash equivalents consist of the following significant asset investment classes as of March 31, 2014 and December 31, 2013 (in thousands):
		March 31, 2014
		Amortized		Unrealized		Unrealized		Fair Value		Cash / Cash		Security
		Cost		Gains		Losses				Equivalents		Classification
	Cash	$	52,906	$	—	$	—	$	52,906	$	52,906	N/A
	Money market fund	54,652		—		—		54,652		54,652		Available for sale
	Total cash and cash equivalents	$	107,558	$	—	$	—	$	107,558	$	107,558
	c	December 31, 2013
		Amortized		Unrealized		Unrealized		Fair Value		Cash / Cash		Security
		Cost		Gains		Losses				Equivalents		Classification
	Cash	$	38,823	$	—	$	—	$	38,823	$	38,823	N/A
	Money market fund	65,708		—		—		65,708		65,708		Available for sale
	Total cash and cash equivalents	$	104,531	$	—	$	—	$	104,531	$	104,531
	The money market fund is a daily-traded cash equivalent with a price of $1.00, making it a Level 1 asset class, and its carrying cost closely approximates fair value. As demand deposit (cash) balances vary with the timing of collections and payments, the money market fund can cover any surplus or deficit, and thus is considered Available-for-sale. We did not hold any Level 2 and Level 3 assets or liabilities as of March 31, 2014 and December 31, 2013.
	The following table shows our financial assets measured at fair value, on a recurring basis, with money market funds recorded within cash and cash equivalents (in thousands):
		Quoted Prices in Active		Total Fair
		Markets for Identical		Value
		Instruments
		(Level 1)
	Money market fund at March 31, 2014	$	54,652	$	54,652
	Money market fund at December 31, 2013	$	65,708	$	65,708

Inventories

Inventories	3 Months Ended
	Mar. 31, 2014
Inventory Disclosure [Abstract]	'
Inventories	'
	Inventories
	Inventories consist of the following (in thousands):
		March 31,		December 31,
		2014		2013
	Raw materials	$	10,278	$	10,765
	Work in process	944		534
	Finished goods	19,753		20,158
	Total	$	30,975	$	31,457

Property_and_Equipment

Property and Equipment	3 Months Ended
	Mar. 31, 2014
Property, Plant and Equipment [Abstract]	'
Property and Equipment	'
	Property and Equipment
	Property and equipment consist of the following (in thousands):
		March 31,			December 31,
		2014			2013
	Equipment	$	40,682		$	40,180
	Furniture and fixtures	5,296			5,260
	Leasehold improvements	7,451			7,394
	Purchased software	21,299			20,199
	Construction in process	3,355			2,649
		78,083			75,682
	Accumulated depreciation and amortization	(42,905		)	(40,428		)
	Property and equipment, net	$	35,178		$	35,254
	Depreciation and amortization of property and equipment totaled approximately $2.5 million and $2.7 million for the three months ended March 31, 2014 and 2013, respectively.

Net_Investment_in_SalesType_Le

Net Investment in Sales-Type Leases	3 Months Ended
	Mar. 31, 2014
Net Investment in Sales-Type Leases Disclosure	'
Net Investment Sales-Type Leases Disclosure [Text Block]	'
	Net Investment in Sales-Type Leases
	Our sales-type leases are for terms generally up to five years. Sales-type lease receivables are collateralized by the underlying equipment. The components of our net investment in sales-type leases are as follows (in thousands):
		March 31,		December 31,
		2014		2013
	Net minimum lease payments to be received	$	18,351	$	18,172
	Less unearned interest income portion	1,397		1,455
	Net investment in sales-type leases	16,954		16,717
	Less current portion(1)	5,310		5,232
	Non-current net investment in sales-type leases(2)	$	11,644	$	11,485
	(1)     A component of other current assets. This amount is net of an immaterial allowance for doubtful accounts as of March 31, 2014 and December 31, 2013.
	(2)     This amount is net of an immaterial allowance for doubtful accounts as of March 31, 2014 and December 31, 2013.
	The minimum lease payments under sales-type leases as of March 31, 2014 were as follows (in thousands):
	Remainder of 2014	$	4,549
	2015	5,230
	2016	3,991
	2017	3,042
	2018	1,466
	Thereafter	73
	Total	$	18,351
	The following table summarizes the credit losses and recorded investment in sales-type leases, excluding unearned interest (in thousands):
		Allowance for Credit Losses		Recorded Investment			Recorded Investment
				in Sales-type Leases Gross			in Sales-type Leases Net
	Credit loss disclosure for March 31, 2014:
	Accounts individually evaluated for impairment	$	—	$	—		$	—
	Accounts collectively evaluated for impairment	169		17,123			16,954
	Ending balances: March 31, 2014	$	169	$	17,123		$	16,954
	Credit loss disclosure for December 31, 2013:
	Accounts individually evaluated for impairment	$	—	$	—		$	—
	Accounts collectively evaluated for impairment	167		16,884			16,717
	Ending balances: December 31, 2013	$	167	$	16,884		$	16,717
	The following table summarizes the activity for the allowance for credit losses for the investment in sales-type leases for the three months ended March 31, 2014 and 2013 (in thousands):
		Three Months Ended March 31,
		2014		2013
	Allowance for credit losses, beginning of period	$	167	$	607
	Current period provision	2		13
	Direct write-downs charged against the allowance	—		(413		)
	Recoveries of amounts previously charged off	—		(17		)
	Allowance for credit losses, end of period	$	169	$	190

Goodwill_and_Other_Intangible_

Goodwill and Other Intangible Assets	3 Months Ended
	Mar. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Goodwill and Other Intangible Assets	'
	Goodwill and Intangible Assets
	Goodwill
	Goodwill is tested for impairment on an annual basis and between annual tests if events or circumstances indicate that an impairment loss may have occurred, and we write down these assets when impaired. We perform our annual impairment tests during the fourth quarter of each fiscal year using the closing balance sheet as of the last day of the third quarter.
	During the three months ended March 31, 2014, we noted no indications of impairment or triggering events to cause us to review goodwill for potential impairment. We will conduct our annual goodwill testing during the fourth fiscal quarter.
	There were no changes in the carrying amount of goodwill for the period from December 31, 2013 to March 31, 2014. Goodwill by reporting unit, which is the same for our operating segments are as follows (in thousands):
		Goodwill at December 31, 2013		Adjustments to Goodwill		Goodwill at March 31, 2014
	Reporting units:
	Automation and Analytics	$	28,543	$	—	$	28,543
	Medication Adherence	82,800		—		82,800
	Total	$	111,343	$	—	$	111,343
	Intangible Assets, net
	There were no indefinite-lived intangible assets as of March 31, 2014 or December 31, 2013. Finite-lived intangible assets consist of the following (in thousands):
		March 31, 2014						December 31, 2013
		Gross				Net		Gross				Net
		Carrying		Accumulated		Carrying		Carrying		Accumulated		Carrying		Amortization
		Amount		Amortization		Amount		Amount		Amortization		Amount		Life
	Finite-lived intangibles:
	Customer relationships	$	54,730	$	5,775	$	48,955	$	54,730	$	5,236	$	49,494	5-30 years
	Acquired technology	27,580		2,965		24,615		27,580		2,598		24,982		3-20 years
	Patents	1,561		303		1,258		1,493		254		1,239		20 years
	Trade name	6,890		1,145		5,745		6,890		1,003		5,887		3-12 years
	Non-compete agreements	—		—		—		60		60		—		3 years
	Total finite-lived intangibles	$	90,761	$	10,188	$	80,573	$	90,753	$	9,151	$	81,602
	Amortization expense totaled $1.1 million for both the three months ended March 31, 2014 and 2013. The amortization of acquired technology is included within product cost of sales and amortization of other acquired intangibles is included within selling, general and administrative expenses.
	Estimated future amortization expense of finite-lived intangible assets are as follows (in thousands):
	Remainder of 2014	$	3,191
	2015	4,225
	2016	3,857
	2017	3,822
	2018	3,714
	Thereafter	61,764
	Total	$	80,573

Accrued_Liabilities

Accrued Liabilities	3 Months Ended
	Mar. 31, 2014
Accrued Liabilities, Current [Abstract]	'
Accrued Liabilities [Text Block]	'
	Accrued Liabilities
	Accrued liabilities consist of the following (in thousands):
		March 31,		December 31,
		2014		2013
	Rebates and lease buyouts	$	2,036	$	1,699
	Advance payments from customers	3,778		4,971
	Accrued Group Purchasing Organization (GPO) fees	2,558		2,324
	Technology license purchase obligation, current portion	1,000		1,500
	Taxes payable	2,406		1,664
	Other	1,716		1,588
	Total	$	13,494	$	13,746

Deferred_Gross_Profit

Deferred Gross Profit	3 Months Ended
	Mar. 31, 2014
Deferred Gross Profit [Abstract]	'
Deferred Gross Profit [Text Block]	'
	Deferred Gross Profit
	Deferred gross profit consists of the following (in thousands):
		March 31,			December 31,
		2014			2013
	Sales of medication and supply dispensing systems and packaging equipment, delivered and invoiced but not yet installed	$	36,151		$	29,040
	Cost of revenues, excluding installation costs	(11,045		)	(9,083		)
	Deferred gross profit	$	25,106		$	19,957

Commitments

Commitments	3 Months Ended
	Mar. 31, 2014
Commitments	'
Commitments Disclosure [Text Block]	'
	Commitments
	We lease properties in California, Florida, Illinois, Tennessee, and the United Kingdom. We also have smaller rented offices in Strongsville, Ohio, the United Arab Emirates, the People's Republic of China and the Federal Republic of Germany.
	At March 31, 2014, the minimum payments under our operating leases for each of the five succeeding fiscal years were as follows (in thousands):
	Remainder of 2014	$	3,538
	2015	5,408
	2016	5,442
	2017	5,178
	2018	4,299
	Thereafter	16,743
	Total	$	40,608
	We purchase components from a variety of suppliers and use contract manufacturers to provide manufacturing services for our products. During the normal course of business, we issue purchase orders with estimates of our requirements several months ahead of the delivery dates. Our near-term commitments to our contract manufacturers and suppliers totaled $9.7 million as of March 31, 2014.

Contingencies

Contingencies	3 Months Ended
	Mar. 31, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Contingencies	'
	Contingencies
	Legal Proceedings
	On March 8, 2013, Bobbi Polanco (“Polanco”) filed a putative class action complaint in the United States District Court for the District of New Jersey (the "Court") against Omnicell and certain of our customers (Case No. 1:13-cv-01417-NLH-KLM) alleging breach of state security notification laws, violations of state consumer fraud laws, fraud, negligence and conspiracy relating to the theft of an Omnicell electronic device containing medication dispensing cabinet log files, including certain patient health information, and subsequent notification of this unauthorized disclosure of personal health information. Polanco is seeking an injunction against the defendants to prevent each of them from committing the acts complained of in the future and monetary damages, costs and expenses. On May 2, 2013, the Court entered an order to show cause which provided, in relevant part, that Polanco is required to show cause as to why the case should not be dismissed for lack of subject matter jurisdiction. On May 13, 2013, Polanco filed an amended complaint. On May 31, 2013, Omnicell filed a motion to dismiss the complaint on the grounds that Polanco failed to satisfy constitutional standing requirements and that she failed to state a claim against Omnicell  for violating  state data breach notification statutes, consumer fraud, common law fraud, negligence and conspiracy. Omnicell also joined in the arguments of the other defendants seeking dismissal. On July 1, 2013, Polanco filed an opposition to the motions to dismiss. On July 15, 2013, Omnicell filed its reply to the opposition from Polanco. In December 2013, the Court granted the defendants' motions to dismiss without prejudice. Polanco failed to file an appeal of the Court's decision by the January 27, 2014 deadline.
	As required under ASC 450, Contingencies, we accrue for contingencies when we believe that a loss is probable and that we can reasonably estimate the amount of any such loss. We did not record any accrual for contingent liabilities associated with the legal proceedings described above based on our belief that any potential loss, while reasonably possible, was not probable. We believe that we have valid defenses with respect to legal proceedings pending against us. However, litigation is inherently unpredictable, and it is possible that cash flows or results of operations could be materially affected in any particular period by the unfavorable resolution of this contingency or because of the diversion of management's attention and the creation of significant expenses.
	Guarantees
	As permitted under Delaware law and our certificate of incorporation and bylaws, we have agreed to indemnify our directors and officers against certain losses that they may suffer by reason of the fact that such persons are, were or become our directors or officers. The term of the indemnification period is for the director’s or officer’s lifetime and there is no limit on the potential amount of future payments that we could be required to make under these indemnification agreements. We have purchased a directors’ and officers’ liability insurance policy that may enable us to recover a portion of any future payments that we may be required to make under these indemnification agreements. Assuming the applicability of coverage and the willingness of the insurer to assume coverage and subject to certain retention, loss limits and other policy provisions, we believe it is unlikely that we will be required to pay any material amounts pursuant to these indemnification obligations. However, no assurances can be given that the insurers will not attempt to dispute the validity, applicability or amount of coverage without expensive and time-consuming litigation against the insurers.
	Additionally, we undertake indemnification obligations in our ordinary course of business in connection with, among other things, the licensing of our products and the provision of our support services. In the ordinary course of our business, we have in the past and may in the future agree to indemnify another party, generally our business affiliates or customers, against certain losses suffered or incurred by the indemnified party in connection with various types of claims, which may include, without limitation, claims of intellectual property infringement, certain tax liabilities, our gross negligence or intentional acts in the performance of support services and violations of laws. The term of these indemnification obligations is generally perpetual. In general, we attempt to limit the maximum potential amount of future payments that we may be required to make under these indemnification obligations to the amounts paid to us by a customer, but in some cases the obligation may not be so limited. In addition, we have in the past and may in the future warrant to our customers that our products will conform to functional specifications for a limited period of time following the date of installation (generally not exceeding 30 days) or that our software media is free from material defects. Sales contracts for certain of our medication packaging systems often include limited warranties for up to six months, but the periodic activity and ending warranty balances we record have historically been immaterial.
	From time to time, we may also warrant that our professional services will be performed in a good and workmanlike manner or in a professional manner consistent with industry standards. We generally seek to disclaim most warranties, including any implied or statutory warranties such as warranties of merchantability, fitness for a particular purpose, title, quality and non-infringement, as well as any liability with respect to incidental, consequential, special, exemplary, punitive or similar damages. In some states, such disclaimers may not be enforceable. If necessary, we would provide for the estimated cost of product and service warranties based on specific warranty claims and claim history. We have not been subject to any significant claims for such losses and have not incurred any material costs in defending or settling claims related to these indemnification obligations. Accordingly, we believe it is unlikely that we will be required to pay any material amounts pursuant to these indemnification obligations or potential warranty claims and, therefore, no material liabilities have been recorded for such indemnification obligations as of March 31, 2014 or December 31, 2013.

Stockholders_Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2014
Stockholders' Equity Note [Abstract]	'
Stockholders' Equity	'
	Stockholders’ Equity
	Treasury Stock
	2012 Stock Repurchase Program
	On August 1, 2012, our Board of Directors established a stock repurchase program (the “2012 Repurchase Program”) authorizing share repurchases of up to $50.0 million of our common stock, with no termination date. The timing, price and volume of repurchases will be based on market conditions, relevant securities laws and other factors. The stock repurchases may be made from time to time on the open market, in privately negotiated transactions or pursuant to a Rule 10b-18 plan. The 2012 Repurchase Program does not obligate us to repurchase any specific number of shares, and we may terminate or suspend the repurchase program at any time.
	For the three months ended March 31, 2014, we repurchased a total of $4.1 million, or 145,737 shares, at an average cost of $27.92, including commissions. We did not repurchase any shares for the three months ended March 31, 2013.
	From the inception of the 2012 Repurchase Program, we have repurchased a total of $25.0 million, or 1,030,382 shares at an average cost of $24.29 per share, including commissions. As of March 31, 2014, the maximum dollar value of shares that may yet be purchased under the plan is $25.0 million.

Stock_Option_Plans_and_ShareBa

Stock Option Plans and Share-Based Compensation	3 Months Ended
	Mar. 31, 2014
Stock Option Plans and Share-Based Compensation [Abstract]	'
Stock Option Plans and Share-Based Compensation	'
	Stock Option Plans and Share-Based Compensation
	Description of Share-Based Plans
	Equity Incentive Plan
	For a detailed explanation of our stock plan and subsequent changes please refer back to our Note 16, Stock Option Plans, Share-Based Compensation and 401(k) Plan on our Annual Report on Form 10-K for the year ended December 31, 2013. At March 31, 2014, 2,457,760 shares of common stock were reserved for future issuance our 2009 Equity Incentive Plan, as amended (the "2009 Plan"), and $6.3 million of total unrecognized compensation cost related to non-vested stock options was expected to be recognized over a weighted average period of 2.8 years.
	A summary of option activity under the 2009 Plan for the three months ended March 31, 2014 is presented below:
	Options:		Number of Shares			Weighted-Average
						Exercise Price
			(in thousands)
	Outstanding at December 31, 2013		3,143			$	15.82
	Granted		241			$	25.43
	Exercised		(401	)		$	15.24
	Forfeited		(38	)		$	16.54
	Expired		(3	)		$	22.99
	Outstanding at March 31, 2014		2,942			$	16.67
	Vested and expected to vest at March 31, 2014		2,909			$	16.61
	Exercisable at March 31, 2014		1,810			$	15.08
	The aggregate intrinsic value of our options is calculated as the difference between the exercise price of the underlying options and the quoted price of our common stock at the end of the reporting period. The aggregate intrinsic value of options exercised under our stock plans for the three months ended March 31, 2014 and March 31, 2013 was $11.4 million and $8.3 million, respectively, determined as of the date of option exercise.
	Restricted Stock and Restricted Stock Units
	A summary of activity of both restricted stock and RSUs for the three months ended March 31, 2014 is presented below:
		Restricted Stock						Restricted Stock Units
		Number of			Weighted-Average			Number of		Weighted-Average
		Shares			Grant Date			Shares		Grant Date
					Fair Value Per					Fair Value Per
					Share					Share
		(in thousands)						(in thousands)
	Non-vested, December 31, 2013	52			$	18.43		362		$	17.15
	Granted	—			$	—		97		$	25.54
	Vested	—			$	—		(31	)	$	15.69
	Forfeited	—			$	—		(14	)	$	15.45
	Non-vested, March 31, 2014	52			$	18.43		414		$	19.27
	The fair value of restricted stock is the product of the number of shares granted and the closing market price of our common stock on the grant date. Our unrecognized compensation cost related to non-vested restricted stock is approximately $7.2 million and is expected to be recognized over a weighted-average period of 2.8 years.
	Performance-Based Restricted Stock Units
	Performance-based restricted stock units ("PSUs") are an element of our executive compensation plans. In 2012, we granted 125,000 PSUs to our executive officer of which 62,500 became eligible for vesting upon the achievement of a certain level of shareholder return for 2012 as described below. In 2013, we granted 137,500 PSUs to our executive officers, all of which became eligible for vesting upon the achievement of a certain level of shareholder return for the period from January 1, 2013 through February 28, 2014, as described below. In 2014, we granted 132,500 PSUs to our executive officers, all, none or a portion of which may become eligible for vesting depending on the level of shareholder return for 2014. For a more detailed explanation of our PSUs and subsequent changes, please refer back to our Note 16, Stock Option Plans, Share-Based Compensation and 401(k) Plan on our Annual Report on Form 10-K for the year ended December 31, 2013.
	Our unrecognized compensation cost related to non-vested performance-based restricted stock units at March 31, 2014 was approximately $2.8 million and is expected to be recognized over a weighted-average period of 1.5 years. For the three months ended March 31, 2014 and 2013, we recognized $0.5 million and $0.4 million, respectively, of compensation expense for the PSUs.
	The following table shows the percent of PSUs granted in 2012 eligible for further time-based vesting based on our percentile placement:
	Percentile Placement of Our Total Shareholder Return	% of PSUs Eligible for Time-
		Based Vesting
	Below the 35th percentile	—%
	At least the 35th percentile, but below the 50th percentile	50%
	At least the 50th percentile	100%
	On January 22, 2013, the Compensation Committee of our Board of Directors ("the Compensation Committee") confirmed 35.3% as the percentile rank of Omnicell's 2012 total stockholder return. This resulted in 50% of the 2012 PSU awards, or 62,500 shares, as eligible for further time-based vesting. The eligible performance-based restricted stock unit awards will vest as follows: 25% of the eligible shares vested immediately on January 22, 2013 with the remaining eligible awards vesting in equal increments, semi-annually, over the subsequent three year period beginning on June 15th and December 15th of the year after the date of grant and each subsequent year. Vesting is contingent upon continued service.
	The following table shows the percent of PSUs granted in 2013 eligible for further time-based vesting based on our percentile placement:
	Percentile Placement of Our Total Shareholder Return	% of PSUs Eligible for Time-
		Based Vesting
	Below the 35th percentile	—%
	At least the 35th percentile, but below the 50th percentile	50%
	At least the 50th percentile	100%
	On March 20, 2014, the Compensation Committee confirmed 63.94% as the percentile rank of Omnicell's 2013-2014 total stockholder return. This resulted in 100% of the 2013 PSU awards, or 137,500 shares, as eligible for further time-based vesting. The eligible performance-based restricted stock unit awards will vest as follows: 25% of the eligible shares vested immediately on March 20, 2014 with the remaining eligible awards vesting in equal increments, semi-annually, over the subsequent three year period beginning on June 15th and December 15th of the year after the date of grant and each subsequent year. Vesting is contingent upon continued service.
	On February 5, 2014, the Compensation Committee approved PSU awards of 132,500 shares. If the minimum performance threshold is met as determined by the Compensation Committee in 2015, the eligible performance-based restricted stock unit awards will vest as follows: 25% of the eligible shares will vest immediately, with the remaining eligible awards vesting in equal increments, semi-annually, over the subsequent three year period beginning on June 15th and December 15th of the year after the date of grant and each subsequent year. Vesting is contingent upon continued service.
	A summary of activity of the PSUs for the three months ended March 31, 2014 is presented below:
	Performance-based Stock Units	Number of Shares			Weighted-Average
					Grant Date
					Fair Value Per
					Share
		(in thousands)
	Non-vested, December 31, 2013	225			$	13.32
	Granted	132			$	16.59
	Vested	(34	)		$	14.81
	Forfeited	—			$	—
	Non-vested, March 31, 2014	323			$	14.41
	1997 Employee Stock Purchase Plan
	We have an Employee Stock Purchase Plan (the “ESPP”) under which employees can purchase shares of our common stock based on a percentage of their compensation, but not greater than 15% of their earnings, up to a maximum of $25,000 of fair value per year. The purchase price per share must be equal to the lower of 85% of the fair value of the common stock at the beginning of a 24-month offering period or the end of each six-month purchasing period.
	At the 2009 Annual Meeting of Stockholders, the stockholders approved an amendment to the ESPP, which added 2,622,426 shares to the reserve for future issuance. As of March 31, 2014, there were 846,891 shares reserved for future issuance under the ESPP. For the three months ended March 31, 2014, 254,009 shares of common stock were purchased under the ESPP. As of March 31, 2014, 4,484,664 shares had been issued under the ESPP.
As of March 31, 2014, our unrecognized compensation cost related to the shares to be purchased under our ESPP was approximately $1.4 million and is expected to be recognized over a weighted average period of 2.0 years.
Share-based Compensation
We account for share-based awards granted to employees and directors, including employee stock option awards, restricted stock, PSUs and RSUs issued pursuant to the 2009 Plan and employee stock purchases made under our ESPP using the estimated grant date fair value method of accounting in accordance with ASC 718, Stock Compensation.
We value options and ESPP shares using the Black-Scholes-Merton option-pricing model. Restricted stock and time-based RSUs are valued at the grant date fair value of the underlying common shares. The PSUs are valued via Monte Carlo simulation.
The impact on our results for share-based compensation was as follows (in thousands):
	Three Months Ended March 31,
	2014				2013
Cost of product and service revenues	$	268			$	305
Research and development expenses	369				289
Selling, general and administrative expenses	2,092				2,332
Total share-based compensation expenses	$	2,729			$	2,926

Segments

Segments	3 Months Ended
	Mar. 31, 2014
Segments [Abstract]	'
Segment Reporting Disclosure [Text Block]	'
	Segments
	Beginning with the acquisition of MTS, which was completed in May 2012, we have organized our business into two operating business segments. Previously, we reported segments based on the customers that our products were sold to, with the Acute Care segment primarily including products and services sold to hospital customers, and the Non-Acute Care segment primarily including products and services sold to customers outside of hospital settings. We are at a point where many of our Acute Care and Non-Acute Care customers are converging to provide services across the continuum of care. These customers seek automation and analytics products that function across the various facilities they manage and we find ourselves providing solutions across multiple types of care environments. These customers are also interested in obtaining higher levels of adherence to prescribed medication regimens that our blister card products provide. Our business has evolved to be managed more on a product basis and it has become more difficult to determine whether a customer is a hospital or a blend of hospitals and non-acute care facilities. Accordingly, beginning in 2014, we have realigned our segments to reflect the products we sell, regardless of who they are sold to.
	The Automation and Analytics segment is organized around the design, manufacturing, selling and servicing of medication and supply dispensing systems, pharmacy inventory management systems, and related software.
	The Medication Adherence segment includes primarily the manufacturing and selling of consumable medication blister cards, packaging equipment and ancillary products and services.
	Prior period amounts in the table below have been recast to conform to the way we internally manage and monitor performance at the segment level during the current period.
	We report segment information based on the management approach. The management approach designates the internal reporting used by the Chief Operating Decision Maker (the "CODM") for making decisions and assessing performance as the source of our operating segments. The CODM is our Chief Executive Officer. The CODM allocates resources to and assesses the performance of each operating segment, using information about its revenues, gross profit and income (loss) from operations. The CODM does not evaluate operating business segments using discrete asset information; accordingly, we do not report segment assets.
	Since 1992, Omnicell has provided automation and business information solutions to healthcare facilities in general, but with a focus on acute care hospitals. We have developed product solutions that help optimize various workflows utilized in hospitals. We have also developed sophisticated sales, installation, and service capabilities to serve the specific and special needs of hospitals. As the healthcare market evolves, acute care facilities are beginning to merge operationally with non-acute care facilities. The new healthcare organizations desire medication and supply inventory control and business analytics across the continuum of care environments they serve. Our Automation and Analytics segment represents the products we sell to fulfill these needs.
	Since 1984, MTS has provided medication adherence solutions to the non-acute care market. These solutions provide automated and semi-automated equipment to assist institutional and retail pharmacists in filling medication orders into blister cards, the primary method of medication control in non-acute care settings. Completing the product solution are the consumables used by institutional and retail pharmacists to make the medication adherence package. MTS has developed process manufacturing capabilities as well as sales capabilities to market medication adherence solutions to institutional and retail pharmacies.
	As healthcare evolves, these medication adherence solutions are finding application in acute care settings as well. Our Medication Adherence segment represents all the products we sell to fulfill medication adherence needs through blister cards, blister card packaging equipment, and related software.
		Three Months Ended March 31, 2014									Three Months Ended March 31, 2013
		Automation and Analytics			Medication Adherence			Total			Automation and Analytics			Medication Adherence			Total
	Total revenues	$	81,499		$	20,265		$	101,764		$	68,713		$	18,397		$	87,110
	Cost of revenues	34,940			12,329			47,269			30,276			11,467			41,743
	Gross profit	$	46,559		$	7,936		$	54,495		$	38,437		$	6,930		$	45,367
	Gross margin %	57.1		%	39.2		%	53.6		%	55.9		%	37.7		%	52.1		%
	Operating expenses	37,402			7,139			44,541			33,104			8,094			41,198
	Income (loss) from operations	$	9,157		$	797		$	9,954		$	5,333		$	(1,164	)	$	4,169
	Operating margin %	11.2		%	3.9		%	9.8		%	7.8		%	(6.3		)%	4.8		%
	Interest and other income (expense), net							(256		)							(223		)
	Income before provision for income taxes							9,698									3,946
	Provision for income taxes							3,504									561
	Net income							$	6,194								$	3,385
	For the three months ended March 31, 2014 and 2013, segment depreciation/amortization, and capital expenditures were as follows (amounts in thousands):
		Three Months Ended March 31, 2014									Three Months Ended March 31, 2013
		Automation and Analytics			Medication Adherence			Total			Automation and Analytics			Medication Adherence			Total
	Depreciation/Amortization	$	2,898		$	1,714		$	4,612		$	2,899		$	1,573		$	4,472
	Capital Expenditures	$	1,748		$	803		$	2,551		$	1,000		$	2,338		$	3,338

Asset_Impairment_Notes

Asset Impairment (Notes)	3 Months Ended
	Mar. 31, 2014
Asset Impairment [Abstract]	'
Impairment of Software Development Costs [Table Text Block]	'
	Impairment of Software Development Costs
	As part of the continuing integration of MTS, in the first quarter of 2013, we reorganized our management team, including the software development department, within the Medication Adherence segment. Through the end of the first quarter of 2013, the Medication Adherence segment had capitalized approximately $1.8 million of software development costs associated with a software solution under development which was intended to assist pharmacies in manual packaging of prescriptions. In connection with our financial statement close process for the quarter ended March 31, 2013, our management reassessed the viability of this project and the net realizable value of capitalized costs in light of its decision to change the related product road map and redesign this product based on evolving market demands. As part of this redesign process, new functionality and capabilities will need to be added to the product before commercialization. This redesign is intended to provide a more robust global platform providing larger scalability and significant functionality not contained in our current beta version. As such, we have determined we can no longer support the technological feasibility of this project in conjunction with our software capitalization policy. Therefore, we charged these costs, in the amount of $1.8 million, ($0.03 per diluted share, net of tax), to expense as a component of research and development in the accompanying condensed consolidated statement of operations.

Credit_Agreement_Notes

Credit Agreement (Notes)	3 Months Ended
	Mar. 31, 2014
Debt Disclosure [Abstract]	'
Debt Disclosure [Text Block]	'
	Credit Agreement
	In September 2013, we entered into a credit agreement (the "Credit Agreement") with Wells Fargo Bank, National Association, as administrative agent, and the lenders from time to time party thereto. The Credit Agreement provides for a $75.0 million revolving credit facility with a $10.0 million letter of credit sub-limit. Loans under the Credit Agreement mature on September 25, 2018. The Credit Agreement permits us to request one or more increases in the aggregate commitments provided that such increases do not exceed $25.0 million in the aggregate. We expect to use the proceeds from any revolving loans under the credit facility for general corporate purposes, including future acquisitions. Our obligations under the Credit Agreement are guaranteed by certain of our domestic subsidiaries and secured by substantially all of our and the subsidiary guarantors’ assets. To date, we have not yet drawn any funds under the credit facility.
	Amounts drawn under the Credit Agreement bear interest, at our election, at a Eurodollar rate plus a margin of 1.75% per annum, or an alternate base rate equal to the highest of (a) the prime rate, (b) the federal funds rate plus 0.50%, and (c) LIBOR for an interest period of one month plus 1.75%. We are required to pay a commitment fee of 0.25% per annum on the aggregate undrawn amount of the commitments under the credit facility.
	The Credit Agreement contains customary affirmative and negative covenants, including, among other things, restrictions on indebtedness, liens, investments, mergers, dispositions, dividends and other distributions. The Credit Agreement contains financial covenants that require us to, among other things, maintain a maximum consolidated total leverage ratio and a minimum consolidated fixed charge coverage ratio, in each case, as of the last day of each fiscal quarter. We were in full compliance with all covenants at March 31, 2014.

Income_Taxes_Notes

Income Taxes (Notes)	3 Months Ended
	Mar. 31, 2014
Income Tax Disclosure [Abstract]	'
Income Tax Disclosure [Text Block]	'
	Income Taxes
	We provide for income taxes for each interim period based on the estimated annual effective tax rate for the year, adjusting for discrete items in the quarter in which they arise. The annual effective tax rate before discrete items was 39.1% and 37.4% for the three-months ended March 31, 2014 and 2013, respectively. The 2014 annual effective tax rate differed from the statutory rate of 35% primarily due to the unfavorable impact of state income taxes, non-deductible equity charges, and other non-deductible expenditures, which were partially offset by the domestic production activities deduction.
	The 2013 annual effective tax rate differed from the statutory rate of 35% primarily due to the unfavorable impact of state income taxes, non-deductible equity charges, and other non-deductible expenditures, which were partially offset by the federal research and development credit claimed and the domestic production activities deduction. The income tax provision for the three months ended March 31, 2013 also reflected a discrete net benefit of $0.7 million, or 18.0% of pre-tax income, related to 2012 federal research and development credit which was retroactively reinstated in the three months ended March 31, 2013.

Organization_and_Summary_of_Si1

Organization and Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Basis of Accounting, Policy [Policy Text Block]	'
	Basis of presentation. These interim condensed consolidated financial statements are unaudited but reflect, in the opinion of management, all adjustments, consisting of normal recurring adjustments and accruals, necessary to present fairly the financial position of Omnicell and its subsidiaries as of March 31, 2014, the results of their operations, comprehensive income and cash flows for the three months ended March 31, 2014 and 2013. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (“GAAP”), have been condensed or omitted in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”). These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and accompanying notes included in our Annual Report on Form 10-K for the year ended December 31, 2013.
	Our results of operations, comprehensive income and cash flows for the three months ended March 31, 2014 are not necessarily indicative of results that may be expected for the year ending December 31, 2014, or for any future period.
Use of Estimates, Policy [Policy Text Block]	'
	Use of estimates. GAAP requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and various other assumptions believed to be reasonable. Although these estimates are based on management's best knowledge of current events and actions that may impact the company in the future, actual results may be different from the estimates. Our critical accounting policies are those that affect our financial statements materially and involve difficult, subjective or complex judgments by management. Those policies are revenue recognition, share-based compensation, inventory valuation, valuation of goodwill and purchased intangibles, valuation of long-lived assets and accounting for income taxes.
Consolidation, Subsidiaries or Other Investments, Consolidated Entities, Policy [Policy Text Block]	'
	Principles of consolidation. The condensed consolidated financial statements include the accounts of our wholly-owned subsidiaries. All significant inter-company accounts and transactions have been eliminated in consolidation
Receivables, Policy [Policy Text Block]	'
	Concentration of credit risk. Financial instruments that may potentially subject us to concentrations of credit risk consist principally of cash equivalents and accounts receivable. Cash equivalents are maintained with several financial institutions and may exceed the amount of insurance provided on such balances. The majority of our accounts receivable are derived from sales to customers for commercial applications. We perform ongoing credit evaluations of our customers’ financial condition and limit the amount of credit extended when deemed necessary but generally require no collateral. We maintain reserves for potential credit losses. Our products are broadly distributed and there was no single customer accounting for 10% or more of revenues in the three months ended March 31, 2014. Additionally, there was no single customer accounting for 10% or more of accounts receivable at March 31, 2014 or December 31, 2013. We believe that we have no significant concentrations of credit risk at March 31, 2014.
New Accounting Pronouncements, Policy [Policy Text Block]	'
	Recently Adopted Accounting Standards
	In July 2013, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2013-11, Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists. ASU 2013-11 requires an entity to present an unrecognized tax benefit, or a portion of an unrecognized tax benefit, as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward, except as follows: to the extent a net operating loss carryforward, a similar tax loss, or a tax credit carryforward is not available at the reporting date under the tax law of the applicable jurisdiction to settle any additional income taxes that would result from the disallowance of a tax position or the tax law of the applicable jurisdiction does not require the entity to use, and the entity does not intend to use, the deferred tax asset for such purpose, the unrecognized tax benefit should be presented in the financial statements as a liability and should not be combined with deferred tax assets. We adopted the amendments in ASU 2013-11 in the first quarter of 2014. This update did not have a significant impact on our financial position, operating results or cash flows.
Earnings Per Share, Policy [Policy Text Block]	'
	Basic net income per share is computed by dividing net income for the period by the weighted average number of shares outstanding during the period, less shares subject to repurchase. Diluted net income per share is computed by dividing net income for the period by the weighted average number of shares, less shares subject to repurchase, plus, if dilutive, potential common stock outstanding during the period. Potential common stock includes the effect of outstanding dilutive stock options, restricted stock awards and restricted stock units computed using the treasury stock method. Since their impact is anti-dilutive, we excluded 347,265 and 1,865,589 shares from the calculations of diluted net income per share for the three months ended March 31, 2014 and 2013, respectively.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	'
	We account for share-based awards granted to employees and directors, including employee stock option awards, restricted stock, PSUs and RSUs issued pursuant to the 2009 Plan and employee stock purchases made under our ESPP using the estimated grant date fair value method of accounting in accordance with ASC 718, Stock Compensation.
	We value options and ESPP shares using the Black-Scholes-Merton option-pricing model. Restricted stock and time-based RSUs are valued at the grant date fair value of the underlying common shares. The PSUs are valued via Monte Carlo simulation

Net_Income_Per_Share_Tables

Net Income Per Share (Tables)	3 Months Ended
	Mar. 31, 2014
Earnings Per Share [Abstract]	'
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	'
	The calculation of basic and diluted net income per share is as follows (in thousands, except per share amounts):
		Three Months Ended March 31,
		2014		2013
	Basic:
	Net income	$	6,194	$	3,385
	Weighted average shares outstanding — basic	35,225		33,900
	Net income per share — basic	$	0.18	$	0.1
	Diluted:
	Net income	$	6,194	$	3,385
	Weighted average shares outstanding — basic	35,225		33,900
	Add: Dilutive effect of employee stock plans	1,080		920
	Weighted average shares outstanding — diluted	36,305		34,820
	Net income per share — diluted	$	0.17	$	0.1

Cash_and_Cash_Equivalents_Shor1

Cash and Cash Equivalents, Short-term Investments and Fair Value of Financial Instruments (Tables)	3 Months Ended
	Mar. 31, 2014
Cash and Cash Equivalents [Abstract]	'
Schedule of Cash, Cash Equivalents and Short-term Investments [Table Text Block]	'
	Cash and cash equivalents consist of the following significant asset investment classes as of March 31, 2014 and December 31, 2013 (in thousands):
		March 31, 2014
		Amortized		Unrealized		Unrealized		Fair Value		Cash / Cash		Security
		Cost		Gains		Losses				Equivalents		Classification
	Cash	$	52,906	$	—	$	—	$	52,906	$	52,906	N/A
	Money market fund	54,652		—		—		54,652		54,652		Available for sale
	Total cash and cash equivalents	$	107,558	$	—	$	—	$	107,558	$	107,558
	c	December 31, 2013
		Amortized		Unrealized		Unrealized		Fair Value		Cash / Cash		Security
		Cost		Gains		Losses				Equivalents		Classification
	Cash	$	38,823	$	—	$	—	$	38,823	$	38,823	N/A
	Money market fund	65,708		—		—		65,708		65,708		Available for sale
	Total cash and cash equivalents	$	104,531	$	—	$	—	$	104,531	$	104,531
Fair Value, Assets Measured on Recurring Basis [Table Text Block]	'
	The following table shows our financial assets measured at fair value, on a recurring basis, with money market funds recorded within cash and cash equivalents (in thousands):
		Quoted Prices in Active		Total Fair
		Markets for Identical		Value
		Instruments
		(Level 1)
	Money market fund at March 31, 2014	$	54,652	$	54,652
	Money market fund at December 31, 2013	$	65,708	$	65,708

Inventories_Tables

Inventories (Tables)	3 Months Ended
	Mar. 31, 2014
Inventory Disclosure [Abstract]	'
Schedule of Inventory, Current [Table Text Block]	'
	Inventories consist of the following (in thousands):
		March 31,		December 31,
		2014		2013
	Raw materials	$	10,278	$	10,765
	Work in process	944		534
	Finished goods	19,753		20,158
	Total	$	30,975	$	31,457

Property_and_Equipment_Tables

Property and Equipment (Tables)	3 Months Ended
	Mar. 31, 2014
Property, Plant and Equipment [Abstract]	'
Property, Plant and Equipment [Table Text Block]	'
	Property and equipment consist of the following (in thousands):
		March 31,			December 31,
		2014			2013
	Equipment	$	40,682		$	40,180
	Furniture and fixtures	5,296			5,260
	Leasehold improvements	7,451			7,394
	Purchased software	21,299			20,199
	Construction in process	3,355			2,649
		78,083			75,682
	Accumulated depreciation and amortization	(42,905		)	(40,428		)
	Property and equipment, net	$	35,178		$	35,254

Net_Investment_in_SalesType_Le1

Net Investment in Sales-Type Leases (Tables)	3 Months Ended
	Mar. 31, 2014
Capital Leases, Net Investment in Sales Type Leases [Abstract]	'
sales type lease investment [Table Text Block]	'
	Our sales-type leases are for terms generally up to five years. Sales-type lease receivables are collateralized by the underlying equipment. The components of our net investment in sales-type leases are as follows (in thousands):
		March 31,		December 31,
		2014		2013
	Net minimum lease payments to be received	$	18,351	$	18,172
	Less unearned interest income portion	1,397		1,455
	Net investment in sales-type leases	16,954		16,717
	Less current portion(1)	5,310		5,232
	Non-current net investment in sales-type leases(2)	$	11,644	$	11,485
Schedule of Future Minimum Lease Payments for Capital Leases [Table Text Block]	'
	The minimum lease payments under sales-type leases as of March 31, 2014 were as follows (in thousands):
	Remainder of 2014	$	4,549
	2015	5,230
	2016	3,991
	2017	3,042
	2018	1,466
	Thereafter	73
	Total	$	18,351
Allowance for Credit Losses on Financing Receivables [Table Text Block]	'
	The following table summarizes the credit losses and recorded investment in sales-type leases, excluding unearned interest (in thousands):
		Allowance for Credit Losses		Recorded Investment			Recorded Investment
				in Sales-type Leases Gross			in Sales-type Leases Net
	Credit loss disclosure for March 31, 2014:
	Accounts individually evaluated for impairment	$	—	$	—		$	—
	Accounts collectively evaluated for impairment	169		17,123			16,954
	Ending balances: March 31, 2014	$	169	$	17,123		$	16,954
	Credit loss disclosure for December 31, 2013:
	Accounts individually evaluated for impairment	$	—	$	—		$	—
	Accounts collectively evaluated for impairment	167		16,884			16,717
	Ending balances: December 31, 2013	$	167	$	16,884		$	16,717
Schedule of Credit Losses Related to Financing Receivables, Noncurrent [Table Text Block]	'
	The following table summarizes the activity for the allowance for credit losses for the investment in sales-type leases for the three months ended March 31, 2014 and 2013 (in thousands):
		Three Months Ended March 31,
		2014		2013
	Allowance for credit losses, beginning of period	$	167	$	607
	Current period provision	2		13
	Direct write-downs charged against the allowance	—		(413		)
	Recoveries of amounts previously charged off	—		(17		)
	Allowance for credit losses, end of period	$	169	$	190

Goodwill_and_Other_Intangible_1

Goodwill and Other Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Schedule of Goodwill [Table Text Block]	'
		Goodwill at December 31, 2013		Adjustments to Goodwill		Goodwill at March 31, 2014
	Reporting units:
	Automation and Analytics	$	28,543	$	—	$	28,543
	Medication Adherence	82,800		—		82,800
	Total	$	111,343	$	—	$	111,343
	Intangible Assets, net
	There were no indefin
Schedule of Intangible Assets and Goodwill [Table Text Block]	'
	There were no indefinite-lived intangible assets as of March 31, 2014 or December 31, 2013. Finite-lived intangible assets consist of the following (in thousands):
		March 31, 2014						December 31, 2013
		Gross				Net		Gross				Net
		Carrying		Accumulated		Carrying		Carrying		Accumulated		Carrying		Amortization
		Amount		Amortization		Amount		Amount		Amortization		Amount		Life
	Finite-lived intangibles:
	Customer relationships	$	54,730	$	5,775	$	48,955	$	54,730	$	5,236	$	49,494	5-30 years
	Acquired technology	27,580		2,965		24,615		27,580		2,598		24,982		3-20 years
	Patents	1,561		303		1,258		1,493		254		1,239		20 years
	Trade name	6,890		1,145		5,745		6,890		1,003		5,887		3-12 years
	Non-compete agreements	—		—		—		60		60		—		3 years
	Total finite-lived intangibles	$	90,761	$	10,188	$	80,573	$	90,753	$	9,151	$	81,602
	Amortization expense totaled $1.1 million for both the three months ended March 31, 2014 and 2013. The amortization of acquired technology is included within product cost of sales and amortization of other acquired intangibles is included within selling, general and administrative expenses.
	Esti
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	'
	Estimated future amortization expense of finite-lived intangible assets are as follows (in thousands):
	Remainder of 2014	$	3,191
	2015	4,225
	2016	3,857
	2017	3,822
	2018	3,714
	Thereafter	61,764
	Total	$	80,573

Accrued_Liabilities_Tables

Accrued Liabilities (Tables)	3 Months Ended
	Mar. 31, 2014
Accrued Liabilities, Current [Abstract]	'
Schedule of Accrued Liabilities [Table Text Block]	'
	Accrued liabilities consist of the following (in thousands):
		March 31,		December 31,
		2014		2013
	Rebates and lease buyouts	$	2,036	$	1,699
	Advance payments from customers	3,778		4,971
	Accrued Group Purchasing Organization (GPO) fees	2,558		2,324
	Technology license purchase obligation, current portion	1,000		1,500
	Taxes payable	2,406		1,664
	Other	1,716		1,588
	Total	$	13,494	$	13,746

Deferred_Gross_Profit_Tables

Deferred Gross Profit (Tables)	3 Months Ended
	Mar. 31, 2014
Deferred Gross Profit [Abstract]	'
Deferred Gross Profit [Table Text Block]	'
	Deferred gross profit consists of the following (in thousands):
		March 31,			December 31,
		2014			2013
	Sales of medication and supply dispensing systems and packaging equipment, delivered and invoiced but not yet installed	$	36,151		$	29,040
	Cost of revenues, excluding installation costs	(11,045		)	(9,083		)
	Deferred gross profit	$	25,106		$	19,957

Commitments_Tables

Commitments (Tables)	3 Months Ended
	Mar. 31, 2014
Commitments [Abstract]	'
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	'
	At March 31, 2014, the minimum payments under our operating leases for each of the five succeeding fiscal years were as follows (in thousands):
	Remainder of 2014	$	3,538
	2015	5,408
	2016	5,442
	2017	5,178
	2018	4,299
	Thereafter	16,743
	Total	$	40,608

Stock_Option_Plans_and_ShareBa1

Stock Option Plans and Share-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2014
Stock Option Plans and Share-Based Compensation [Abstract]	'
PSU % eligible vesting vs Total Shareholder Return - Second year [Table Text Block]	'
	The following table shows the percent of PSUs granted in 2012 eligible for further time-based vesting based on our percentile placement:
	Percentile Placement of Our Total Shareholder Return	% of PSUs Eligible for Time-
		Based Vesting
	Below the 35th percentile	—%
	At least the 35th percentile, but below the 50th percentile	50%
	At least the 50th percentile	100%
Schedule of Stock Options Roll Forward [Table Text Block]	'
	A summary of option activity under the 2009 Plan for the three months ended March 31, 2014 is presented below:
	Options:		Number of Shares			Weighted-Average
						Exercise Price
			(in thousands)
	Outstanding at December 31, 2013		3,143			$	15.82
	Granted		241			$	25.43
	Exercised		(401	)		$	15.24
	Forfeited		(38	)		$	16.54
	Expired		(3	)		$	22.99
	Outstanding at March 31, 2014		2,942			$	16.67
	Vested and expected to vest at March 31, 2014		2,909			$	16.61
	Exercisable at March 31, 2014		1,810			$	15.08
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block]	'
	A summary of activity of both restricted stock and RSUs for the three months ended March 31, 2014 is presented below:
		Restricted Stock						Restricted Stock Units
		Number of			Weighted-Average			Number of		Weighted-Average
		Shares			Grant Date			Shares		Grant Date
					Fair Value Per					Fair Value Per
					Share					Share
		(in thousands)						(in thousands)
	Non-vested, December 31, 2013	52			$	18.43		362		$	17.15
	Granted	—			$	—		97		$	25.54
	Vested	—			$	—		(31	)	$	15.69
	Forfeited	—			$	—		(14	)	$	15.45
	Non-vested, March 31, 2014	52			$	18.43		414		$	19.27
	The fair value of restricted stock is the product of the number of shares granted and the closing market price of our common stock on the grant date. Our unrecognized compensation cost related to non-vested restricted stock is approximately $7.2 million and is expected to be recognized over a weighted-average period of 2.8 years.
PSU % eligible vesting vs total Shareholder Return placement - First year [Table Text Block]	'
	A summary of activity of the PSUs for the three months ended March 31, 2014 is presented below:
	Performance-based Stock Units	Number of Shares			Weighted-Average
					Grant Date
					Fair Value Per
					Share
		(in thousands)
	Non-vested, December 31, 2013	225			$	13.32
	Granted	132			$	16.59
	Vested	(34	)		$	14.81
	Forfeited	—			$	—
	Non-vested, March 31, 2014	323			$	14.41
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	'
	The impact on our results for share-based compensation was as follows (in thousands):
		Three Months Ended March 31,
		2014				2013
	Cost of product and service revenues	$	268			$	305
	Research and development expenses	369				289
	Selling, general and administrative expenses	2,092				2,332
	Total share-based compensation expenses	$	2,729			$	2,926

Segments_Tables

Segments (Tables)	3 Months Ended
	Mar. 31, 2014
Segment Reporting Information [Line Items]	'
Segment Reporting Disclosure [Text Block]	'
	Segments
	Beginning with the acquisition of MTS, which was completed in May 2012, we have organized our business into two operating business segments. Previously, we reported segments based on the customers that our products were sold to, with the Acute Care segment primarily including products and services sold to hospital customers, and the Non-Acute Care segment primarily including products and services sold to customers outside of hospital settings. We are at a point where many of our Acute Care and Non-Acute Care customers are converging to provide services across the continuum of care. These customers seek automation and analytics products that function across the various facilities they manage and we find ourselves providing solutions across multiple types of care environments. These customers are also interested in obtaining higher levels of adherence to prescribed medication regimens that our blister card products provide. Our business has evolved to be managed more on a product basis and it has become more difficult to determine whether a customer is a hospital or a blend of hospitals and non-acute care facilities. Accordingly, beginning in 2014, we have realigned our segments to reflect the products we sell, regardless of who they are sold to.
	The Automation and Analytics segment is organized around the design, manufacturing, selling and servicing of medication and supply dispensing systems, pharmacy inventory management systems, and related software.
	The Medication Adherence segment includes primarily the manufacturing and selling of consumable medication blister cards, packaging equipment and ancillary products and services.
	Prior period amounts in the table below have been recast to conform to the way we internally manage and monitor performance at the segment level during the current period.
	We report segment information based on the management approach. The management approach designates the internal reporting used by the Chief Operating Decision Maker (the "CODM") for making decisions and assessing performance as the source of our operating segments. The CODM is our Chief Executive Officer. The CODM allocates resources to and assesses the performance of each operating segment, using information about its revenues, gross profit and income (loss) from operations. The CODM does not evaluate operating business segments using discrete asset information; accordingly, we do not report segment assets.
	Since 1992, Omnicell has provided automation and business information solutions to healthcare facilities in general, but with a focus on acute care hospitals. We have developed product solutions that help optimize various workflows utilized in hospitals. We have also developed sophisticated sales, installation, and service capabilities to serve the specific and special needs of hospitals. As the healthcare market evolves, acute care facilities are beginning to merge operationally with non-acute care facilities. The new healthcare organizations desire medication and supply inventory control and business analytics across the continuum of care environments they serve. Our Automation and Analytics segment represents the products we sell to fulfill these needs.
	Since 1984, MTS has provided medication adherence solutions to the non-acute care market. These solutions provide automated and semi-automated equipment to assist institutional and retail pharmacists in filling medication orders into blister cards, the primary method of medication control in non-acute care settings. Completing the product solution are the consumables used by institutional and retail pharmacists to make the medication adherence package. MTS has developed process manufacturing capabilities as well as sales capabilities to market medication adherence solutions to institutional and retail pharmacies.
	As healthcare evolves, these medication adherence solutions are finding application in acute care settings as well. Our Medication Adherence segment represents all the products we sell to fulfill medication adherence needs through blister cards, blister card packaging equipment, and related software.
		Three Months Ended March 31, 2014									Three Months Ended March 31, 2013
		Automation and Analytics			Medication Adherence			Total			Automation and Analytics			Medication Adherence			Total
	Total revenues	$	81,499		$	20,265		$	101,764		$	68,713		$	18,397		$	87,110
	Cost of revenues	34,940			12,329			47,269			30,276			11,467			41,743
	Gross profit	$	46,559		$	7,936		$	54,495		$	38,437		$	6,930		$	45,367
	Gross margin %	57.1		%	39.2		%	53.6		%	55.9		%	37.7		%	52.1		%
	Operating expenses	37,402			7,139			44,541			33,104			8,094			41,198
	Income (loss) from operations	$	9,157		$	797		$	9,954		$	5,333		$	(1,164	)	$	4,169
	Operating margin %	11.2		%	3.9		%	9.8		%	7.8		%	(6.3		)%	4.8		%
	Interest and other income (expense), net							(256		)							(223		)
	Income before provision for income taxes							9,698									3,946
	Provision for income taxes							3,504									561
	Net income							$	6,194								$	3,385
	For the three months ended March 31, 2014 and 2013, segment depreciation/amortization, and capital expenditures were as follows (amounts in thousands):
		Three Months Ended March 31, 2014									Three Months Ended March 31, 2013
		Automation and Analytics			Medication Adherence			Total			Automation and Analytics			Medication Adherence			Total
	Depreciation/Amortization	$	2,898		$	1,714		$	4,612		$	2,899		$	1,573		$	4,472
	Capital Expenditures	$	1,748		$	803		$	2,551		$	1,000		$	2,338		$	3,338
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]	'
		Three Months Ended March 31, 2014									Three Months Ended March 31, 2013
		Automation and Analytics			Medication Adherence			Total			Automation and Analytics			Medication Adherence			Total
	Total revenues	$	81,499		$	20,265		$	101,764		$	68,713		$	18,397		$	87,110
	Cost of revenues	34,940			12,329			47,269			30,276			11,467			41,743
	Gross profit	$	46,559		$	7,936		$	54,495		$	38,437		$	6,930		$	45,367
	Gross margin %	57.1		%	39.2		%	53.6		%	55.9		%	37.7		%	52.1		%
	Operating expenses	37,402			7,139			44,541			33,104			8,094			41,198
	Income (loss) from operations	$	9,157		$	797		$	9,954		$	5,333		$	(1,164	)	$	4,169
	Operating margin %	11.2		%	3.9		%	9.8		%	7.8		%	(6.3		)%	4.8		%
	Interest and other income (expense), net							(256		)							(223		)
	Income before provision for income taxes							9,698									3,946
	Provision for income taxes							3,504									561
	Net income							$	6,194								$	3,385
Schedule of Segment Reporting Information, by Segment [Table Text Block]	'
	For the three months ended March 31, 2014 and 2013, segment depreciation/amortization, and capital expenditures were as follows (amounts in thousands):
		Three Months Ended March 31, 2014									Three Months Ended March 31, 2013
		Automation and Analytics			Medication Adherence			Total			Automation and Analytics			Medication Adherence			Total
	Depreciation/Amortization	$	2,898		$	1,714		$	4,612		$	2,899		$	1,573		$	4,472
	Capital Expenditures	$	1,748		$	803		$	2,551		$	1,000		$	2,338		$	3,338

Organization_and_Summary_of_Si2

Organization and Summary of Significant Accounting Policies Risks - concentration Revenue and Acct Rec, trading and H-T-M amounts (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013	Mar. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Schedule of Available-for-sale Securities [Line Items]	'	'	'	'
Cash and cash equivalents	$107,558	$104,531	$69,817	$62,313
Money Market Funds [Member]	'	'	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'	'	'
Cash and cash equivalents	54,652	65,708	'	'
Cash and Cash Equivalents, Fair Value Disclosure	$54,652	$65,708	'	'

Organization_and_Summary_of_Si3

Organization and Summary of Significant Accounting Policies Significant supplier disclosure (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Unusual Risk or Uncertainty [Line Items]	'	'
Purchases from significant supplier	$8.90	$7.20

Organization_and_Summary_of_Si4

Organization and Summary of Significant Accounting Policies Income tax disclosure (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Income Tax Contingency [Line Items]	'	'
effective tax rate before discrete items	39.10%	37.40%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate	35.00%	'
Income Tax Expense (Benefit)	$3,504	$561

Organization_and_Summary_of_Si5

Organization and Summary of Significant Accounting Policies Accounts Receivable Concentration (Details)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013
	customer	customer	customer
Concentration Risk [Line Items]	'	'	'
customers with 10% revenue concentration	0	0	'
customers with 10 % accts rec concentration	0	'	0

Net_Income_Per_Share_Details

Net Income Per Share (Details) (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Earnings Per Share [Abstract]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	347,265	1,865,589
Earnings Per Share, Basic [Abstract]	'	'
Net income	$6,194	$3,385
Weighted Average Number of Shares Outstanding, Basic	35,225,000	33,900,000
Net income per share-basic	$0.18	$0.10
Earnings Per Share, Diluted [Abstract]	'	'
Weighted Average Number of Shares Outstanding, Basic	35,225,000	33,900,000
Dilutive Effect of Employee Stock Plans	$1,080	$920
Weighted Average Number of Shares Outstanding, Diluted	36,305,000	34,820,000
Net income per share - diluted	$0.17	$0.10

Cash_and_Cash_Equivalents_Shor2

Cash and Cash Equivalents, Short-term Investments and Fair Value of Financial Instruments (Details) avail for sasle securities levels 1-2-3 table (USD $)	3 Months Ended
	Mar. 31, 2014	Dec. 31, 2013
Cash and Cash Equivalents [Line Items]	'	'
Money Market Fund - daily traded value	$1	'
Cash, Cash Equivalents, and Short-term Investments	107,558,000	104,531,000
Money Market Funds [Member]	'	'
Cash and Cash Equivalents [Line Items]	'	'
Cash and Cash Equivalents, Fair Value Disclosure	54,652,000	65,708,000
Money Market Funds [Member] | Fair Value, Measurements, Recurring [Member]	'	'
Cash and Cash Equivalents [Line Items]	'	'
Cash and Cash Equivalents, Fair Value Disclosure	54,652,000	65,708,000
Money Market Funds [Member] | Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]	'	'
Cash and Cash Equivalents [Line Items]	'	'
Cash and Cash Equivalents, Fair Value Disclosure	$54,652,000	$65,708,000

Cash_and_Cash_Equivalents_Shor3

Cash and Cash Equivalents, Short-term Investments and Fair Value of Financial Instruments marketable securities - gain or loss (Details) (USD $)	3 Months Ended
	Mar. 31, 2014	Dec. 31, 2013	Mar. 31, 2013	Dec. 31, 2012
Schedule of Available-for-sale Securities [Line Items]	'	'	'	'
Money Market Fund - daily traded value	$1	'	'	'
Cash and cash equivalents, Amortized Cost	107,558,000	104,531,000	69,817,000	62,313,000
Cash, cash equiv and S-T-I: Amortized cost	107,558,000	104,531,000	'	'
Cash, cash equiv and S-T-I: Gross unrealized gains	0	0	'	'
Cash, cash equiv and S-T-I: Gross unrealized losses	0	0	'	'
Cash, Cash Equivalents, and Short-term Investments	107,558,000	104,531,000	'	'
Cash [Member]	'	'	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'	'	'
Cash and cash equivalents, Amortized Cost	52,906,000	38,823,000	'	'
Cash and cash equivalents - gross unrealized gain	0	0	'	'
Cash and cash equivalents - Gross unrealized losses	0	0	'	'
Cash and Cash Equivalents, Fair Value Disclosure	52,906,000	38,823,000	'	'
Money Market Funds [Member]	'	'	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'	'	'
Cash and cash equivalents, Amortized Cost	54,652,000	65,708,000	'	'
Cash and cash equivalents - gross unrealized gain	0	0	'	'
Cash and cash equivalents - Gross unrealized losses	0	0	'	'
Cash and Cash Equivalents, Fair Value Disclosure	54,652,000	65,708,000	'	'
Cash and Cash Equivalents [Member]	'	'	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'	'	'
Cash, Cash Equivalents, and Short-term Investments	107,558,000	104,531,000	'	'
Cash and Cash Equivalents [Member] | Cash [Member]	'	'	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'	'	'
Cash and Cash Equivalents, Fair Value Disclosure	52,906,000	38,823,000	'	'
Cash and Cash Equivalents [Member] | Money Market Funds [Member]	'	'	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'	'	'
Cash and Cash Equivalents, Fair Value Disclosure	$54,652,000	$65,708,000	'	'

Inventories_Details

Inventories (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Inventory [Abstract]	'	'
Raw materials	$10,278	$10,765
Work in process	944	534
Finished goods	19,753	20,158
Total	$30,975	$31,457

Property_and_Equipment_Details

Property and Equipment (Details) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013
Property, Plant and Equipment [Line Items]	'	'	'
Property and Equipment, Gross	$78,083,000	'	$75,682,000
Accumulated Depreciation	-42,905,000	'	-40,428,000
Property and equipment, net	35,178,000	'	35,254,000
Depreciation expense	2,500,000	2,700,000	'
Equipment [Member]	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Property and Equipment, Gross	40,682,000	'	40,180,000
Furniture and Fixtures [Member]	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Property and Equipment, Gross	5,296,000	'	5,260,000
Leasehold Improvements [Member]	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Property and Equipment, Gross	7,451,000	'	7,394,000
Software [Member]	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Property and Equipment, Gross	21,299,000	'	20,199,000
Construction in Progress [Member]	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Property and Equipment, Gross	$3,355,000	'	$2,649,000

Net_Investment_in_SalesType_Le2

Net Investment in Sales-Type Leases sales type lease - from min payments to non current investment (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013
Net Investment in Sales-Type Leases [Abstract]	'	'
Sales Type Leases, Lease Term	'5 years	'
Net minimum lease payments to be received	$18,351	$18,172
Less unearned interest income portion	1,397	1,455
Net investment in sales-type leases	16,954	16,717
Less current portion	5,310	5,232
Non-current net investment in sales-type leases	$11,644	$11,485

Net_Investment_in_SalesType_Le3

Net Investment in Sales-Type Leases (Details) (USD $)	Mar. 31, 2014
In Thousands, unless otherwise specified
Net Investment in Sales-Type Leases [Abstract]	'
Remainder of 2014	$4,549
2015	5,230
2016	3,991
2017	3,042
2018	1,466
Thereafter	73
Total	$18,351

Net_Investment_in_SalesType_Le4

Net Investment in Sales-Type Leases Credit loss balances by evaluation method for impairment (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013	Mar. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Financing Receivable, Allowance for Credit Losses [Line Items]	'	'	'	'
Financing Receivable, Allowance for Credit Losses, Individually Evaluated for Impairment	$0	$0	'	'
Financing Receivable Gross - individually evaluated for impairment	0	0	'	'
Financing Receivable, Individually Evaluated for Impairment	0	0	'	'
Financing Receivable, Allowance for Credit Losses, Collectively Evaluated for Impairment	169	167	'	'
Financing Receivable Gross - collectively evalauated for impairment	17,123	16,884	'	'
Financing Receivable, Collectively Evaluated for Impairment	16,954	16,717	'	'
Financing Receivable, Allowance for Credit Losses	169	167	190	607
Financing Receivable, Gross	17,123	16,884	'	'
Financing Receivable, Net	$16,954	$16,717	'	'

Net_Investment_in_SalesType_Le5

Net Investment in Sales-Type Leases allowance credit loss rollforward (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Financing Receivable, Allowance for Credit Losses [Roll Forward]	'	'
Allowance for credit losses, beginning of period	$167	$607
Current period provision (reversal)	2	13
Direct write-downs charged against the allowance	0	-413
Recoveries of amounts previously charged off	0	-17
Allowance for credit losses, end of period	$169	$190

Goodwill_and_Other_Intangible_2

Goodwill and Other Intangible Assets Goodwill rollforward by segment (details) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Goodwill [Line Items]	'	'
Amortization of Intangible Assets	$1,100,000	$1,100,000
Goodwill [Roll Forward]	'	'
Goodwill, Beginning balance	111,343,000	'
Goodwill acquired	0	'
Goodwill, Ending balance	111,343,000	'
Automation and Analytics [Member]	'	'
Goodwill [Roll Forward]	'	'
Goodwill, Beginning balance	28,543,000	'
Goodwill acquired	0	'
Goodwill, Ending balance	28,543,000	'
Medication Adherence [Member]	'	'
Goodwill [Roll Forward]	'	'
Goodwill, Beginning balance	82,800,000	'
Goodwill acquired	0	'
Goodwill, Ending balance	$82,800,000	'

Goodwill_and_Other_Intangible_3

Goodwill and Other Intangible Assets Finite life intangibles Gross and Net at balance sheet dates (Details) (USD $)

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

In Thousands, unless otherwise specified

Customer Relationships [Member]

Customer Relationships [Member]

acquired technology [Member]

acquired technology [Member]

Patents [Member]

Patents [Member]

Patents [Member]

Trade Names [Member]

Trade Names [Member]

Noncompete Agreements [Member]

Noncompete Agreements [Member]

Noncompete Agreements [Member]

Minimum [Member]

Minimum [Member]

Minimum [Member]

Maximum [Member]

Maximum [Member]

Maximum [Member]

Customer Relationships [Member]

acquired technology [Member]

Trade Names [Member]

Customer Relationships [Member]

acquired technology [Member]

Trade Names [Member]

Acquired Finite-Lived Intangible Assets [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Finite-Lived Intangible Assets, Gross

$90,761

$90,753

$54,730

$54,730

$27,580

$27,580

'

$1,561

$1,493

$6,890

$6,890

'

$0

$60

'

'

'

'

'

'

Finite-Lived Intangible Assets, Accumulated Amortization

10,188

9,151

5,775

5,236

2,965

2,598

'

303

254

1,145

1,003

'

0

60

'

'

'

'

'

'

Finite-Lived Intangible Assets, Net

$80,573

$81,602

$48,955

$49,494

$24,615

$24,982

'

$1,258

$1,239

$5,745

$5,887

'

$0

$0

'

'

'

'

'

'

Finite-Lived Intangible Asset, Useful Life

'

'

'

'

'

'

'20 years

'

'

'

'

'3 years

'

'

'5 years

'3 years

'3 years

'30 years

'20 years

'12 years

Goodwill_and_Other_Intangible_4

Goodwill and Other Intangible Assets Amortization expense (finite life intangibles) (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'	'
Amortization of Intangible Assets	$1.10	$1.10

Goodwill_and_Other_Intangible_5

Goodwill and Other Intangible Assets Future amortizaion of intangibles (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Goodwill and Intangible Assets Disclosure [Abstract]	'	'
2015	$3,191	'
2016	4,225	'
2017	3,857	'
2018	3,822	'
Finite-Lived Intangible Assets, Amortization Expense, Year Five	3,714	'
Thereafter	61,764	'
Finite-Lived Intangible Assets, Net	$80,573	$81,602

Goodwill_and_Other_Intangible_6

Goodwill and Other Intangible Assets Indefinite Life Intangibles by class (Details) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012
Goodwill and Intangible Assets Disclosure [Abstract]	'	'	'	'
Indefinite-Lived Intangible Assets (Excluding Goodwill)	'	'	$0	$0
Amortization of Intangible Assets	$1,100,000	$1,100,000	'	'

Accrued_Liabilities_Details

Accrued Liabilities (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Accrued Liabilities, Current [Abstract]	'	'
Advance payments from customers	$3,778	$4,971
Accrued Group Purchasing Organization (GPO) fees	2,558	2,324
technologylicensepurchaseobigationcurrent	1,000	1,500
Rebates and lease buyouts	2,036	1,699
Taxes payable	2,406	1,664
Other	1,716	1,588
Total	$13,494	$13,746

Deferred_Gross_Profit_Details

Deferred Gross Profit (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Deferred Gross Profit [Abstract]	'	'
Sales of Medication and supply dispensing systems and packaging equipment, which have been delivered and invoiced but not yet installed	$36,151	$29,040
Cost of revenues, excluding installation costs	-11,045	-9,083
Deferred gross profit	$25,106	$19,957

Commitments_Details

Commitments (Details) (USD $)	Mar. 31, 2014
In Thousands, unless otherwise specified
Commitments [Abstract]	'
2015	$3,538
2016	5,408
2017	5,442
2018	5,178
Operating Leases, Future Minimum Payments, Due in Five Years	4,299
Thereafter	16,743
Total	$40,608

Commitments_supplier_obligatio

Commitments supplier obligation (Details) (USD $)	Mar. 31, 2014
In Millions, unless otherwise specified
Commitments [Abstract]	'
Purchase Commitment, Remaining Minimum Amount Committed	$9.70

Contingencies_Details

Contingencies (Details)	9 Months Ended
	Sep. 30, 2012
Product Liability Contingency [Line Items]	'
Net Amount at Risk by Product and Guarantee, Weighted Average Period Remaining	'30 days
Medication Packaging Systems [Member]	'
Product Liability Contingency [Line Items]	'
Net Amount at Risk by Product and Guarantee, Weighted Average Period Remaining	'6 months

Stockholders_Equity_Details

Stockholders' Equity (Details) (USD $)	3 Months Ended			20 Months Ended	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014	Mar. 31, 2014	Mar. 31, 2014	Mar. 31, 2013
			2012 Repurchase Program [Member]	2012 Repurchase Program [Member]	Performance Shares [Member]	Performance Shares [Member]
Class of Stock [Line Items]	'	'	'	'	'	'
Allocated Share-based Compensation Expense	$2,729,000	$2,926,000	'	'	$500,000	$400,000
Stock Repurchase Program, Authorized Amount	'	'	50,000,000	'	'	'
Payments for Repurchase of Common Stock	4,069,000	0	4,064,000	25,000,000	'	'
Treasury Stock, Shares, Acquired	'	'	145,737	1,030,382	'	'
Treasury Stock Acquired, Average Cost Per Share	'	'	$27.92	$24.29	'	'
Stock Repurchase Program, Remaining Authorized Repurchase Amount	'	'	$25,000,000	'	'	'

Stock_Option_Plans_and_ShareBa2

Stock Option Plans and Share-Based Compensation Narrative (Details) (USD $)	3 Months Ended
In Millions, except Share data, unless otherwise specified	Mar. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Common Stock, Capital Shares Reserved for Future Issuance	2,457,760
Performance Shares [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	132,000
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition	'1 year 6 months 6 days
2009 Equity Incentive Plan [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition	'2 years 9 months 7 days
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized	6.3

Stock_Option_Plans_and_ShareBa3

Stock Option Plans and Share-Based Compensation Stock option rollforward YTD (Details) (USD $)	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014
In Millions, except Share data, unless otherwise specified			Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	2,909,000	'	'
Common Stock, Capital Shares Reserved for Future Issuance	2,457,760	'	'
Options, shares outstanding- Period start	'	'	3,143,000
Options, Outstanding, Wtd Avg Exercise Price - Period start	'	'	$15.82
Options, Shares Granted in Period	'	'	241,000
Options, Grants in Period, Wtd Avg Exercise Price	'	'	$25.43
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	'	'	-401,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price	'	'	$15.24
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period	'	'	-38,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price	'	'	$16.54
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period	'	'	-3,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price	'	'	$22.99
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	1,810,000	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price	$16.61	'	'
Options, shares outstanding- Period end	'	'	2,942,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$15.08	'	'
Options, Outstanding, Wtd Avg Exercise Price - Period end	'	'	$16.67
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value	$11.40	$8.30	'

Stock_Option_Plans_and_ShareBa4

Stock Option Plans and Share-Based Compensation Restricted Stock Awards and RSUs rollforward (Details) (USD $)	3 Months Ended
In Millions, except Share data, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013
Restricted Stock [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Share-based Awards Other than Options	$7.20	'
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition	'2 years 9 months	'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number	52,000	52,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value	$18.43	$18.43
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	0	'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value	$0	'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period	0	'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value	$0	'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period	0	'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value	$0	'
Restricted Stock Units (RSUs) [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number	414,000	362,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value	$19.27	$17.15
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	97,000	'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value	$25.54	'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period	-31,000	'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value	$15.69	'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period	-14,000	'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value	$15.45	'
Performance Shares [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Share-based Awards Other than Options	$2.80	'
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition	'1 year 6 months 6 days	'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number	323,000	225,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value	$14.41	$13.32
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	132,000	'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value	$16.59	'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period	34,000	'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value	$14.81	'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period	0	'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value	$0	'

Stock_Option_Plans_and_ShareBa5

Stock Option Plans and Share-Based Compensation Performance based stock units (PSU) (Details) (USD $)

3 Months Ended

0 Months Ended

3 Months Ended

0 Months Ended

12 Months Ended

3 Months Ended

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Mar. 20, 2014

Mar. 31, 2014

Jan. 22, 2013

Dec. 31, 2012

Mar. 31, 2014

Mar. 31, 2014

Performance Shares [Member]

Performance Shares [Member]

Performance Shares [Member]

Performance Shares [Member]

2013 PSU [Member]

2013 PSU [Member]

2012 PSU [Member]

2012 PSU [Member]

Minimum [Member]

Maximum [Member]

Performance Shares [Member]

Performance Shares [Member]

Performance Shares [Member]

Performance Shares [Member]

Below the 75th percentile ranking [Member]

Below the 75th percentile ranking [Member]

PSU program year one [Member]

PSU program year one [Member]

Performance Shares [Member]

Performance Shares [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

PSU percentage eligible for time-based vesting

'

'

'

'

'

'

'

'

'

'

110.00%

119.00%

Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Share-based Awards Other than Options

'

'

$2,800,000

'

'

'

'

'

'

'

'

'

Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition

'

'

'1 year 6 months 6 days

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number

'

'

323,000

'

225,000

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value

'

'

$14.41

'

$13.32

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period

'

'

132,000

'

'

'

'

132,500

'

125,000

'

'

PSU shares eligible for vesting based on actual shareholder return

'

'

'

'

'

'

137,500

'

62,500

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, First Year Share Vesting Rate

'

'

'

'

'

'

25.00%

'

25.00%

'

'

'

Share-based Compensation Arrangement By Share-based Payment Award, Number Of Shares Eligible For Vesting

'

'

'

'

'

62,500

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period

'

'

-34,000

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value

'

'

$16.59

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value

'

'

$14.81

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period

'

'

0

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value

'

'

$0

'

'

'

'

'

'

'

'

'

Allocated Share-based Compensation Expense

$2,729,000

$2,926,000

$500,000

$400,000

'

'

'

'

'

'

'

'

PSU percentage eligible for vesting based on actual return

'

'

'

'

'

'

100.00%

'

50.00%

'

'

'

Stock_Option_Plans_and_ShareBa6

Stock Option Plans and Share-Based Compensation PSU performance to vesting table by Program year (Details) (USD $)

Mar. 31, 2014

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2014

Dec. 31, 2014

Dec. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Jan. 22, 2013

Dec. 31, 2012

Mar. 20, 2014

Mar. 31, 2014

Performance Shares [Member]

Performance Shares [Member]

Employee Stock [Member]

Below the 35th percentile ranking [Member]

Below 50th percentile ranking [Member]

At least 50th percentile (after yr one) [Member]

Minimum [Member]

Maximum [Member]

2012 PSU [Member]

2012 PSU [Member]

2013 PSU [Member]

2013 PSU [Member]

PSU Program Year Three [Domain]

PSU Program Year Three [Domain]

PSU Program Year Three [Domain]

Below the 75th percentile ranking [Member]

Below the 75th percentile ranking [Member]

Performance Shares [Member]

Performance Shares [Member]

Performance Shares [Member]

Performance Shares [Member]

Performance Shares [Member]

Performance Shares [Member]

Performance Shares [Member]

PSU program year one [Member]

PSU program year one [Member]

Performance Shares [Member]

Performance Shares [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentile Ranking of 2012 Shareholder Return

'

'

'

'

'

'

'

'

'

35.30%

'

'

'

Shares, Issued

'

'

'

4,484,664

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number

'

323,000

225,000

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value

'

$14.41

$13.32

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period

'

132,000

'

'

'

'

'

'

'

'

125,000

'

132,500

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value

'

$16.59

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period

'

-34,000

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value

'

$14.81

'

'

'

'

'

'

'

'

'

'

'

PSU percentage eligible for time-based vesting

'

'

'

'

0.00%

50.00%

100.00%

110.00%

119.00%

'

'

'

'

PSU percentage eligible for vesting based on actual return

'

'

'

'

'

'

'

'

'

50.00%

'

100.00%

'

PSU shares eligible for vesting based on actual shareholder return

'

'

'

'

'

'

'

'

'

62,500

'

137,500

'

Share-based Compensation Arrangement by Share-based Payment Award, First Year Share Vesting Rate

'

'

'

'

'

'

'

'

'

25.00%

'

25.00%

'

Percentile Ranking of 2013 Shareholder Return

'

'

'

'

'

'

'

'

'

'

'

63.94%

'

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period

'

0

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value

'

$0

'

'

'

'

'

'

'

'

'

'

'

Common Stock, Capital Shares Reserved for Future Issuance

2,457,760

'

'

846,891

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period

'

'

'

254,009

'

'

'

'

'

'

'

'

'

Stock_Option_Plans_and_ShareBa7

Stock Option Plans and Share-Based Compensation ESPP- Employee stock purchase plan (Details) (USD $)	3 Months Ended
	Mar. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Common Stock, Capital Shares Reserved for Future Issuance	2,457,760
Employee Stock [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
ESPP max percent of earnings contributable	15.00%
ESPP max annual contribution	$25,000
ESPP purchase price as percent of begin and-or ending fair value	85.00%
Shares, Issued	4,484,664
Common Stock, Capital Shares Reserved for Future Issuance	846,891
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period	254,009
Employee Stock Purchase Plan [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized	2,622,426
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options	$1,439,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	'2 years 0 months

Stock_Option_Plans_and_ShareBa8

Stock Option Plans and Share-Based Compensation Stock expense by P&L caption (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Allocated Share-based Compensation Expense	$2,729	$2,926
Cost of Sales [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Allocated Share-based Compensation Expense	268	305
Research and Development Expense [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Allocated Share-based Compensation Expense	369	289
Selling, General and Administrative Expenses [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Allocated Share-based Compensation Expense	$2,092	$2,332

Segments_Details

Segments (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Segment Reporting Information [Line Items]	'	'
Depreciation and amortization	$4,612	$4,472
Property, Plant and Equipment, Additions	2,551	3,338
Revenues	101,764	87,110
Cost of Revenue	47,269	41,743
Gross profit	54,495	45,367
Gross Margin Percentage	53.60%	52.10%
Operating Expenses	44,541	41,198
Income from operations	9,954	4,169
Operating margin percentage	9.80%	4.80%
Interest and other income (expense), net	-256	-223
Income before provision for income taxes	9,698	3,946
Provision for income taxes	3,504	561
Net income	6,194	3,385
Automation and Analytics [Member]	'	'
Segment Reporting Information [Line Items]	'	'
Depreciation and amortization	2,898	2,899
Property, Plant and Equipment, Additions	1,748	1,000
Revenues	81,499	68,713
Cost of Revenue	34,940	30,276
Gross profit	46,559	38,437
Gross Margin Percentage	57.10%	55.90%
Operating Expenses	37,402	33,104
Income from operations	9,157	5,333
Operating margin percentage	11.20%	7.80%
Medication Adherence [Member]	'	'
Segment Reporting Information [Line Items]	'	'
Depreciation and amortization	1,714	1,573
Property, Plant and Equipment, Additions	803	2,338
Revenues	20,265	18,397
Cost of Revenue	12,329	11,467
Gross profit	7,936	6,930
Gross Margin Percentage	39.20%	37.70%
Operating Expenses	7,139	8,094
Income from operations	$797	($1,164)
Operating margin percentage	3.90%	-6.30%

Asset_Impairment_Details

Asset Impairment (Details) (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Asset Impairment [Abstract]	'	'
Impairment of software development costs	$0	$1,759
Change in accounting estimate impact on dilted eps	'	$0.03

Credit_Agreement_Details

Credit Agreement (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014
Line of Credit Facility [Line Items]	'
Line of Credit Facility, Maximum Borrowing Capacity	$75
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage	0.25%
Potential Increase in Aggregate Commitments [Member]	'
Line of Credit Facility [Line Items]	'
Line of Credit Facility, Maximum Borrowing Capacity	25
Letter of Credit [Member]	'
Line of Credit Facility [Line Items]	'
Line of Credit Facility, Maximum Borrowing Capacity	$10
Eurodollar Rate [Member]	'
Line of Credit Facility [Line Items]	'
Debt Instrument, Basis Spread on Variable Rate	1.75%
Federal Funds Rate [Member]	'
Line of Credit Facility [Line Items]	'
Debt Instrument, Basis Spread on Variable Rate	0.50%
LIBOR [Member]	'
Line of Credit Facility [Line Items]	'
Debt Instrument, Basis Spread on Variable Rate	1.75%

Income_Taxes_Details

Income Taxes (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Income Taxes [Abstract]	'	'
effective tax rate before discrete items	39.10%	37.40%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	35.00%	'
Effective Income Tax Rate Reconciliation, Other Adjustments, Amount	$700	'
Effective Income Tax Rate Reconciliation, Other Adjustments, Percent	18.00%	'